Procyon Company Executives
| PCYN Stock | USD 0.24 0.01 4.35% |
Procyon employs about 19 people. The company is managed by 3 executives with a total tenure of roughly 24 years, averaging almost 8.0 years of service per executive, having 6.33 employees per reported executive. Analysis of Procyon's management performance can provide insight into the firm performance.
| James Anderson Director CFO, Director and VP of Operations - Amerx Health Care Corporate |
| Justice Anderson Insider Pres CEO |
Procyon |
Procyon Management Team Effectiveness
The company has return on total asset (ROA) of (0.0501) % which means that it has lost $0.0501 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0934) %, meaning that it created substantial loss on money invested by shareholders. Procyon's management efficiency ratios could be used to measure how well Procyon manages its routine affairs as well as how well it operates its assets and liabilities.Procyon Workforce Comparison
Procyon is rated below average in number of employees category among its peers. The total workforce of Drug Manufacturers—Specialty & Generic industry is at this time estimated at about 21,507. Procyon adds roughly 19.0 in number of employees claiming only tiny portion of equities under Drug Manufacturers—Specialty & Generic industry.
The company has Profit Margin (PM) of (0.05) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.07) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.07. Procyon Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Procyon Price Series Summation is a cross summation of Procyon price series and its benchmark/peer.
Procyon Notable Stakeholders
A Procyon stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Procyon often face trade-offs trying to please all of them. Procyon's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Procyon's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| James Anderson | CFO, Director and VP of Operations - Amerx Health Care Corporate | Profile | |
| George Borak | VP of Sales - Amerx Health Care Corp | Profile | |
| Justice Anderson | Pres CEO | Profile |
About Procyon Management Performance
The success or failure of an entity such as Procyon often depends on how effective the management is. Procyon management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Procyon management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Procyon management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Procyon Corporation, together with its subsidiaries, develops and markets proprietary medical products for use in the treatment of pressure ulcers, stasis ulcers, wounds, dermatitis, inflammation, and other skin problems in the United States. The company was incorporated in 1987 and is based in Oldsmar, Florida. Procyon Corp operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 19 people.
Procyon Workforce Analysis
Traditionally, organizations such as Procyon use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Procyon within its industry.Procyon Manpower Efficiency
Return on Procyon Manpower
| Revenue Per Employee | 254.9K | |
| Revenue Per Executive | 1.6M | |
| Net Loss Per Employee | 11K | |
| Net Loss Per Executive | 69.9K | |
| Working Capital Per Employee | 54.7K | |
| Working Capital Per Executive | 346.4K |
Other Information on Investing in Procyon Pink Sheet
Procyon financial ratios help investors to determine whether Procyon Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Procyon with respect to the benefits of owning Procyon security.